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Abstract  
 
Childhood obesity occurs as the result of an imbalance between caloric intake and energy 
expenditure. Genetic risk factors for obesity have become an area of research due to its 
permanency. Mutated genes such as Fat Mass and Obesity Associated (FTO), Leptin 
(LEP), Leptin Receptor (LEPR), Melanocortin 4 Receptor (MC4R), Adiponectin C1Q 
and Collagen Domain Containing (ADIPOQ), Proprotein Convertase Subtilisin/Kexin 
Type 1 (PCSK1), and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) all 
contribute to the development of childhood obesity. In the presence of high cholesterol 
caused by obesity, the genetic condition known as familial hypercholesterolemia is 
exacerbated. Familial hypercholesterolemia is caused by a mutation in the following 
genes: Low Density Lipoprotein Receptor (LDLR), Apolipoprotein B (APOB), Low 
Density Lipoprotein Receptor Adaptor Protein 1 (LDLRAP1), and the Proprotein 
Convertase Subtillisin/Kexin Type 9 (PCSK9). Familial hypercholesterolemia and 
childhood obesity both contribute to elevated serum cholesterol levels resulting in the 
accelerated progression of atherosclerosis in children. Another sequela of 
hypercholesterolemia, atherosclerosis, is an arterial disease that contributes to the 
development of cardiovascular disease in children. Nurses play a prominent role in the 
prevention of childhood obesity through education within the community and school 
setting. As a result of childhood obesity and familial hyperlipidemia, both genetically-
linked, cardiovascular disease has become prevalent in the pediatric population. 
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Childhood Obesity and Familial Hypercholesterolemia: Genetic Diseases that Contribute 
to Cardiovascular Disease 
Childhood obesity has reached epidemic levels in the United States, now 
becoming the main health concern for children. Although obesity is caused by both 
modifiable and nonmodifiable risk factors, research has recently focused on the genetic 
background of obesity due to its permanency. Childhood obesity results from the 
overconsumption of calories combined with a decreased caloric expenditure; genetic 
mutations that contribute to obesity are located within this spectrum of energy balance. 
Additionally, childhood obesity is closely correlated with a diet high in fat, leading to the 
development of high cholesterol in children. In the presence of high circulating 
cholesterol levels familial hypercholesterolemia, a genetic lipid regulation disease is 
exacerbated resulting in increased cholesterol levels. Each of these conditions contributes 
to the development and progression of atherosclerosis in children. Familial 
hypercholesterolemia and childhood obesity, both genetically linked disease processes, 
are major risk factors for the development of atherosclerosis and the development of 
cardiovascular disease in children and adolescents. 
Childhood Obesity 
Definition 
Pediatric obesity is a rapidly growing disease process that affects children of all 
ages. Obesity is defined as “the result of chronic energy imbalance in a person who 
consistently takes in more calories from food and drink than are needed to power their 
body’s metabolic and physical functions” (Centers for Disease Control and Prevention, 
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2013a, para.1). Excess intake of calories with decreased physical activity leads to the 
accumulation of fat. Childhood obesity is known as obesity that occurs in children and 
adolescents ages 2 to 19 years old. This condition is determined based on the child’s body 
mass index (BMI). Body mass index (BMI) indirectly measures body fat based on the 
child’s weight and height; age and sex-specific percentiles are used to determine BMI in 
children, rather than categories which are used for adults (Centers for Disease Control 
and Prevention, 2012). Percentiles represent how the child’s weight and height correlate 
to other children of the same age and gender (American Heart Association, 2011). A 
child is deemed overweight if the BMI is between the 85th and 95th percentile, and obese
if the BMI is above the 95th percentile (Centers for Disease Control and Prevention,
2012). Figure 1 illustrates how a child’s height, weight, and age determine body mass 
index (BMI), the measuring tool for obesity. 
Statistics 
Unfortunately, childhood obesity has become a common occurrence in children 
across the United States, becoming more accepted and even expected in culture. 
Currently, one-third of children in the United States are either overweight or obese, 
tripling the amount of obese children from the past decades (American Heart Association, 
2011). Approximately 13 million children ages 2 to 19 years old are obese, accounting 
for 16.9% of children in the United States. Divided into age groups, 8.4% of children 
ages 2 to 5 years old are obese, 17.7% of 6 to 11 year-olds are obese, and 20.5% of 12 to 
19 year-olds are obese (Food Research and Action Center, 2010). 
Figure 1: Example of a growth chart with various BMI for a ten year-old male 
(Centers for Disease Control and Prevention, 2011) 
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The effects of childhood obesity extend across the borders of the United States and affect 
many children worldwide. According to the World Health Organization, “childhood 
obesity is one of the most serious public health challenges of the 21st century” (World
Health Organization, 2014, para.1). As of 2010, the amount of overweight children under 
the age of five was approximately 42 million worldwide, with 35 million in developing 
countries (World Health Organization, 2014). Globally, instead of the focus being on 
underweight and malnourished children, the focus has shifted to overweight and obese 
children. Figure 2 depicts the increasing trend of obesity from 1963 to 2008 among 
various pediatric age groups. Figure 3 depicts the number of obese high school students 
in the USA based on state and location. The effect of obesity is not specific to one age 
group, but rather affects children of all ages, races, and gender (American Heart 
Association, 2011).  Additionally, these drastic increases in obesity prevalence have 
occurred in a relatively short time period of 30 years. 
Childhood obesity has become the primary health concern for children across the 
nation due to association with chronic disease that previously has not been seen until 
adulthood (American Heart Association, 2011). Chronic diseases are many times 
preventable and unfortunately are now occurring in childhood. Before the wide 
prevalence of obesity, childhood was always thought to be the healthiest time period in 
life; however, this ideal is changing. This disease process has exploded into epidemic 
proportions, and as a result, children are now at risk of dying before their parents. 
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Former Surgeon General Richard Carmona stated, “because of the increasing rates of 
obesity, unhealthy eating habits and physical inactivity, we may see the first generation 
that will be less healthy and have a shorter life expectancy than their parents” (American 
Heart Association, 2011, p.1). Studies have shown that one-third of obese children will 
become obese adults, indicating that lifestyle and health in childhood is a major predictor 
of health as an adult (Bouchard, 2009). As a result of obesity, children are living lower 
quality of lives and have an increased risk of mortality at an earlier age. 
Pathophysiology 
Childhood obesity begins at the cellular level and occurs as a compensatory 
mechanism for an increase in caloric consumption. Energy metabolism is measured in 
calories, which are units of heat derived from food sources (Pleuss & Matfin, 2009). 
Figure 3: Percentage of obese high school students in 2011 based on state (Centers for 
Disease Control and Prevention, 2013a) 
Removed for copyright purposes
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Approximately 90% of energy in the body is stored in adipose tissue. Adipocytes are fat 
cells, located throughout the body, and are responsible for the accumulation, synthesis, 
storage, and utilization of lipids, which are the primary source of energy for the body. 
Mature, or differentiated adipocyte cells do not divide; however, immature adipocytes or 
pre-adipocytes are capable of division; therefore, pre-adipocytes are responsible for fat 
deposition throughout the body. In the process of fat tissue production, an increase in the 
consumption of lipids causes an increase in the amount of pre-adipocytes, which are 
capable of fat storage (Pleuss & Matfin, 2009). 
 Two varieties of adipose tissue are present in the human body: white fat and 
brown fat. White fat is the most prevalent form of fat tissue in the child and adult body. 
Triglycerides, produced by white fat, are a major source of energy for the body. Brown 
fat found in neonates, produces heat for the body, and is not involved in lipid storage. 
Adipocytes are also responsible for the production of leptin, a hormone indicated in the 
regulation of food intake and energy expenditure. Leptin attaches to leptin receptors and 
functions by increasing energy expenditure and decreasing food intake. In the absence of 
obesity, adipocytes remain at a relatively consistent amount; however, when obesity 
occurs, more adipocytes are required for fat storage and utilization. Childhood obesity is 
a result of the dysfunction of the body’s normal fat storage process (Pleuss & Matfin, 
2009).  
Risk Factors 
Modifiable risk factors. Obesity in childhood results from the combination of 
modifiable and non-modifiable risk factors. Modifiable risk factors include risk factors 
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that can be altered or changed such as diet, sedentary lifestyle, psychological factors, 
socioeconomic factors, and parental obesity (Pleuss & Matfin, 2009). Diet is a major risk 
factor for childhood obesity due to the consumption of foods high in fat and sugar, larger 
portion sizes, and increased intake of fast foods. Sadly, french fries are the most common 
source of vegetable consumed by children (American Heart Association, 2011). Children 
many times do not control their diet and eat what is provided; therefore, parents have a 
responsibility to insure a balanced and nutritious diet is consumed. Along with a poor 
diet, many children also live a very sedentary lifestyle, spending many hours watching 
television, playing video games, and using the computer. The average child spends 44.5 
hours a week using the television, computer, and video games. Studies have shown that 
people usually eat while watching television and that each additional hour in television 
viewing is associated with consuming 167 calories. An increased amount of time 
watching television leads to overconsumption of calories creating a cycle of sedentary 
activity and overeating. Lastly, parental obesity is a main risk factor for childhood 
obesity. Children with one parent who is obese have a 79% likelihood of becoming 
overweight as an adult (Pleuss & Matfin, 2009). Many times a child cannot control 
parental weight or lifestyle behavior; however, parental obesity is a risk factor that can be 
changed. Although childhood obesity has become prevalent in society, modifiable risk 
factors such as diet, sedentary lifestyle, and parental obesity can be changed. 
Non-modifiable risk factors. Non-modifiable risk factors for childhood obesity 
are permanent and cannot be changed. These risk factors include genetics, race, and a 
family history of obesity (Pleuss & Matfin, 2009). Due to the permanency of these risk 
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factors, they have become a subject of study to determine the impact they have on 
childhood obesity. Genetic factors include genetic mutations that alter physiologic 
processes and predispose to obesity. Race is a non-modifiable risk factor for obesity. 
Studies have shown that African American, Hispanic American, and Native American 
children have a higher prevalence of obesity than Caucasian children. Obesity rates for 
females ages 2 to 19 years old based on race include: 15.6% of Caucasians, 20.5% of 
African Americans, and 20.6% of Hispanic Americans (Food Research and Action 
Center, 2010). Obesity rates for males ages 2 to 19 years old based on race include: 
12.6% of Caucasians, 19.9% of African Americans, and 24.1 % of Hispanic Americans. 
Native American children obesity data is not available. It is unclear whether the increased 
prevalence is related to racial factors or socioeconomic status. A family history of obesity 
may be the result of a genetic predisposition within the family; however, a child will 
typically follow the role models within the family (Pleuss & Matfin, 2009). Non-
modifiable risk factors cannot be changed; therefore, it is important to screen children for 
the presence of these factors in order to understand their risk of becoming obese. 
Genetic Links of Childhood Obesity 
Due to the increasing prevalence of childhood obesity, research is currently 
focusing on genetic links that lead to the development of obesity. Genes provide detailed 
instructions for the body to carry out required daily functions. Additionally, genes 
instruct the body how to react to positive and negative changes within the environment 
(Centers for Disease Control and Prevention, 2013b). Mutations in specific genes alter 
the function of the gene and what it is responsible to produce. Although genetic 
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alterations in the human population occur at too slow of a rate to be responsible for the 
current obesity epidemic, variations in how individuals respond to similar environments 
indicate that genes play a role in the development of obesity. Obesity most likely is not a 
monogenetic condition, but is most likely a result of multiple genes and interactions 
within the individual’s environment. Genes cannot be completely responsible for obesity, 
but in the presence of an obesogenic environment, these mutated genes are enhanced, and 
a child’s probability of becoming obese greatly increases. An obesogenic environment 
offers easy access to high-calorie foods with limited physical activity (Centers for 
Disease Control and Prevention, 2013a). 
Approximately 5% of childhood obesity cases are the result of a mutated gene, 
and less than 5% of these implicated genes have been discovered (Bouchard, 2009). 
Human genome studies have revealed over 50 genes that are associated with obesity 
(Centers for Disease Control and Prevention, 2013a). As research continues concerning 
genetic links to obesity, the amount of genetic mutations responsible for obesity is likely 
to increase. Genes that have been studied and contribute to obesity include: Fat Mass and 
Obesity Associated (FTO), Leptin (LEP), Leptin Receptor (LEPR), Melanocortin 4 
Receptor (MC4R), Adiponectin C1Q and Collagen Domain Containing (ADIPOQ), 
Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), and Peroxisome Proliferator-
Activated Receptor Gamma (PPARG) (Centers for Disease Control and Prevention, 
2013a). Childhood obesity results from a mutation of the various genes which all encode 
instructions for differing processes. 
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Fat mass and obesity associated gene. Fat Mass and Obesity Associated (FTO) 
is a discovered gene that contributes to the development of childhood obesity. Fat Mass 
and Obesity Associated gene, also known as ALKBH9, is located on the long arm of 
chromosome 16 shown in Figure 4, and is 
a nuclear protein of the AlkB non-haem 
iron and 2-oxoglutarate-dependent 
oxygenase superfamily (Genetics Home 
Reference, 2013b). The exact physiologic 
function of the FTO gene is unknown, but 
is thought to regulate metabolic rate, 
energy expenditure, energy balance, body size, and body fat accumulation (UniProt, 
2014). Mutations in the FTO gene interrupt the normal function and thus predispose to 
childhood obesity. When the FTO gene is mutated, it is associated with increased energy 
consumption and impairs the individual’s response to satiety (Garver, 2011). As a result, 
children’s ability to determine satiety is altered, resulting in hyperphagia. Additionally, 
current society promotes increased serving sizes, further exacerbating the problem of 
hyperphagia. Studies have shown FTO gene variants predispose an individual to an 
increased consumption of calorie-dense foods that are high in fat (Garver, 2011). A diet 
high in fat also contributes to high cholesterol, an associated condition with childhood 
obesity. The FTO gene predisposes children of all ages to obesity. 
Leptin gene. Leptin (LEP) gene mutation contributes to the development of 
childhood obesity. The leptin gene, located on the long arm of chromosome 7 shown in 
Figure 4: FTO Gene 
(Genetics Home Reference, 2013b) 
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Figure 5, encodes a protein that is secreted by white adipocytes and assists to regulate 
body weight (Genetics Home 
Reference, 2013c). As stated 
above, white adipose tissue is 
responsible for fat storage. This 
protein functions via the leptin 
receptor and operates as a 
signaling pathway that can inhibit food intake and regulate energy expenditure to 
maintain a balance of adipose mass. Due to a gene mutation, the LEP gene’s ability to 
inhibit food intake is altered predisposing a child to severe obesity. The LEP gene is 
unable to inhibit food intake, predisposing to overconsumption of calories and an 
increase in adipose tissue (Genetics Home Reference, 2013c). 
Leptin receptor gene. The Leptin Receptor (LEPR) gene helps to regulate body 
weight; however, when the gene is mutated, this contributes to childhood obesity. This 
gene is located on the short arm of chromosome 1 shown in Figure 6 and provides 
instructions for the 
production of leptin 
receptor, a protein 
involved in body 
weight regulation 
(Genetics Home 
Reference, 2013d). 
Figure 5: LEP Gene (Genetics Home Reference, 2013c) 
Figure 6: LEPR Gene (Genetics Home Reference, 2013d) 
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Leptin receptor proteins are found on cells throughout the body, and are activated by the 
binding of leptin. The binding of leptin to leptin receptors activates a chemical signal and 
produces satiety. Normally, adipose cells secrete leptin in direct proportion to the size 
and amount of adipose cells. An increased amount of adipose tissue results in the 
increased production of leptin. Mutations in LEPR gene result in leptin receptor 
deficiency, which leads to excessive hunger and significant weight gain. Deficiency of 
leptin receptors results in hyperphagia and subsequently, obesity (Genetics Home 
Reference, 2013e).  Leptin receptor deficiency is an inherited autosomal recessive 
condition and is responsible for approximately 3% of individuals with childhood obesity 
and overeating. Autosomal recessive inheritance requires both parents to pass on the 
mutated gene to their offspring in order for the mutation to present clinically. Based on 
the inheritance pattern, children are born with this condition, predisposing them from 
birth to be overweight and obese (Genetics Home Reference, 2013e). Leptin receptor 
gene mutation is a minor yet concrete contributor to the development of obesity in the 
pediatric population. 
Melanocortin 4 receptor gene. Melanocortin 4 Receptor (MC4R) gene 
contributes to childhood obesity through the dysfunction of energy balance. Located on 
the long arm of chromosome 18 shown in Figure 7, the MC4R gene is involved in energy 
homeostasis and somatic growth (Genetics Home Reference, 2014e).  Melanocortin 4 
Receptor is a membrane-bound protein receptor that interacts with adrenocorticotropic 
(ACTH) and melanocyte-stimulating hormone (MSH). This protein is activated by 
binding with MSH, and results in a reduction of caloric intake and an increase in energy 
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expenditure via thermogenesis (Garver, 2011). Mutations of the MC4R gene cause 
individuals to consume an increased amount of 
food, specifically a preference for total and 
saturated fats. Mutations of this gene predispose 
children to the development of high cholesterol as 
a result of increased fat consumption. Additionally, 
MC4R mutations result in a decreased feeling of 
satiety and an increase in weight accumulation and thus, the resulting childhood obesity. 
Melanocortin 4 Receptor mutation, along with an obesogenic environment and 
prevalence of high-fat food, increases a child’s risk of becoming obese (Garver, 2011). 
Adiponectin C1Q and collagen domain containing gene. Adiponectin C1Q and 
Collagen Domain Containing (ADIPOQ) gene contributes to the development of 
childhood obesity 
through the dysfunction 
of fat metabolism 
(Genetics Home 
Reference, 2013a). 
Adiponectin C1Q and 
Collagen Domain Containing gene, located on the long arm of chromosome 3 shown in 
Figure 8, is involved in metabolic processes. This gene is solely present in adipose tissue 
and encodes for a protein that is involved in fat metabolism and insulin sensitivity. 
Adiponectin C1Q and Collagen Domain Containing gene stimulates AMPK 
Figure 7: MC4R Gene 
 (Genetics Home Reference, 2014e) 
Figure 8: ADIPOQ Gene (Genetics Home Reference, 2013) 
Removed for 
copyright purposes
Removed for 
copyright purposes
CHILDHOOD OBESITY 17
phosphorylation in the skeletal muscle in the liver, resulting in glucose and fatty-acid 
combustion and metabolism. Mutation of the ADIPOQ gene is associated with 
adiponectin deficiency. Adiponectin deficiency impairs fat metabolism, therefore 
predisposing fat accumulation and obesity. Decreased fat metabolism contributes to the 
accumulation of adipose tissue, the defining factor in obesity (Genetics Home Reference, 
2013a). 
Proprotein convertase subtilisin/kexin type 1 gene. Childhood obesity occurs 
partially as a result of the mutation of the Proprotein Convertase Subtilisin/Kexin Type 1 
(PCSK1) gene. This 
gene is located on the 
long arm of 
chromosome 5 shown 
in Figure 9, and plays a 
role in the production of 
insulin (Genetics Home Reference, 2014f). Normally, PCSK1 encodes for a protein, a 
type 1 proinsulin-processing enzyme that activates latent precursor proteins to their 
usable state. The type 1 proinsulin-processing enzyme regulates insulin biosynthesis. 
Mutations of this gene contribute to the development of obesity, due to dysfunctional 
insulin synthesis. As a result of PCSK1 gene mutation, children are predisposed to 
obesity (Genetics Home Reference, 2014f). 
Peroxisome prolifertor-activated receptor gamma gene. Peroxisome 
Proliferator-Activated Receptor Gamma (PPARG) gene mutation results in the loss of 
Figure 9: PCSK1 Gene (Genetics Home Reference, 2014f) 
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control of fat tissue differentiation. Peroxisome Proliferator-Activated Receptor Gamma 
is located on the short arm of chromosome 3 shown in Figure 10 (Genetics Home 
Reference, 2014h). Normally, the PPARG gene encodes various nuclear receptors of the 
peroxisome 
proliferator-
activated receptor 
subfamily (PPAR): 
PPAR-alpha, 
PPAR-delta, and 
PPAR-gamma. Specifically, the PPARG gene encodes for PPAR-gamma, which is 
involved in the regulation of adipocyte differentiation. As stated above, adipocyte 
differentiation includes mature, or differentiated adipocytes, and immature adipocytes 
(Pleuss & Matfin, 2009). Differentiated adipocytes do not divide, and immature 
adipocytes are capable of division; therefore, pre-adipocytes are responsible for fat 
deposition throughout the body. With a mutation in adipocyte differentiation, pre-
adipocyte cells can divide uncontrollably and increase the amount of adipose tissue. 
Obesity, diabetes, atherosclerosis, hypertension, and cancer are all associated with a 
mutation of the PPARG gene (Genetics Home Reference, 2014h). As a result of PPARG 
gene mutations children are predisposed to various chronic diseases, including obesity. 
Hypercholesterolemia 
Gene mutations implicated in childhood obesity occur in the process of energy 
balance. Many mutations as stated above predispose children to a high fat diet, a known 
Figure 10: PPARG Gene (Genetics Home Reference, 2014h) 
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contributor to childhood obesity and hypercholesterolemia. High cholesterol in children 
is known to be associated with childhood obesity (The Cleveland Clinic Foundation, 
2013). Hypercholesterolemia occurs when high levels of cholesterol are in the 
bloodstream (Genetics Home Reference, 2014b). This condition can result from genetic 
mutations, primary hypercholesterolemia, or lifestyle factors referred to as secondary 
hypercholesterolemia (Matfin, 2009). Familial hypercholesterolemia is primary 
hypercholesterolemia as a result of genetic mutations. Secondary hypercholesterolemia in 
children is linked with diet and obesity (The Cleveland Clinic Foundation, 2013). An 
obese child’s diet is many times composed of foods high in fat and sugar, and deficient in 
essential nutrients. This diet is associated with secondary hypercholesterolemia as a result 
of excess cholesterol availability, leading to increased cholesterol in the bloodstream. 
Cholesterol. Cholesterol is a fat-like substance that is abundant in the diet of 
obese children. Functionally, cholesterol is a building block of cell membranes, 
hormones, and produces compounds that are involved in fat digestion (Genetics Home 
Reference, 2014b). Sources of this substance include foods such as egg yolks, meat, 
poultry, fish, and dairy products. The digestive tract absorbs cholesterol, and then 
transports it into the vasculature via lipoproteins; lipoproteins are composed of a lipid in 
the interior and proteins surrounding the exterior (National Human Genome Research 
Institute, 2013). There are two variations of lipoproteins: low density lipoprotein (LDL) 
and high density lipoprotein (HDL); appropriate levels of LDL and HDL are shown in 
Figure 11. LDL and HDL function oppositely within the body. 
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LDL cholesterol. Low density lipoproteins, referred to as bad cholesterol, is the 
primary carrier of cholesterol and is composed of 10% triglycerides, 50% cholesterol, and 
25% protein (Matfin, 2009). LDL is removed from the bloodstream mainly via LDL 
receptors, but also by monocytes or macrophages. Body tissues are able to control their 
cholesterol intake by increasing or decreasing the amount of LDL receptors. The amount 
of plasma LDL is directly controlled by the removal of LDL by monocytes and 
macrophages; when LDL is absorbed by macrophages, located in the walls of arteries, the 
development of atherosclerosis begins. Increased LDL levels are the main contributor to 
the development of atherosclerosis, which is discussed later (Matfin, 2009). 
HDL cholesterol. High density lipoprotein is beneficial to the body and helps to 
control cholesterol. HDL, known as good cholesterol, is composed of 5% triglycerides, 
20% cholesterol, and 50% protein (Matfin, 2009). Functionally, HDL cholesterol 
operates opposite of LDL by removing cholesterol from tissues and transporting it to the 
liver for excretion. By promoting the removal of LDL from the body, HDL helps to 
decrease to risk of atherosclerosis. HDL has arterial protective functions by preventing 
Figure 11: Cholesterol levels in children (Eiland & Luttrell, 2010) 
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the uptake of LDL by macrophages therefore decreasing atherosclerosis. Overall, 
children need adequate levels of HDL to combat the effects of LDL (Matfin, 2009). 
Familial Hypercholesterolemia 
Definition. 
High cholesterol in children can be caused by diet or genetic mutations. Familial 
hypercholesterolemia is a genetically linked disease that is exacerbated by the presence of 
childhood obesity and high cholesterol. Familial hypercholesterolemia is an “inherited 
condition that causes high levels of LDL cholesterol levels beginning at birth and heart 
attacks at an early age” (National Human Genome Research Institute, 2013, para.1). 
Circulating high cholesterol within the vasculature, combined with the dysfunction in 
LDL removal results in extremely high levels of serum cholesterol predisposing children 
to cardiovascular events. 
This condition is an 
autosomal dominant 
disease, which “refers to a 
gene on one of the 22 pairs 
of autosomes (non-sex 
chromosomes) [and] 
describes a trait or disorder in which the phenotype is expressed in those who have 
inherited only one copy of a particular gene mutation” (Seal, 2011, p. 62). Due to the 
inheritance pattern, if one parent has this genetic defect they have a 50% chance of 
passing the disease to their offspring. Figure 12 illustrates familial 
Figure 12: Autosomal Dominant inheritance pattern of 
Familial Hypercholesterolemia (FH Foundation, 2014) 
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hypercholesterolemia’s inheritance pattern. Familial hypercholesterolemia results from 
mutations of LDLR, APOB, LDLRAP1, and PCSK9 genes (Genetics Home Reference, 
2014b). Gene mutations cause an inability to remove LDL from the bloodstream resulting 
in high levels of LDL cholesterol (National Genome Research Institute, 2013). 
According to the American Academy of Pediatrics, FH screening is recommended in 
children after age 2 and before age 10 “if a family has a pattern of early heart attacks or 
heart disease defined as before age 55 for men and 65 for women” (FH Foundation, 2014, 
para. 8). Children are diagnosed with familial hypercholesterolemia if their total 
cholesterol is above 250 mg/dL and LDL is above 200 mg/dL. This condition affects 
approximately one in 500 people worldwide (Genetics Home Reference, 2014b). Familial 
hypercholesterolemia is a result of genetic mutations, altering the body’s normal 
function. 
Genetic Links to Familial Hypercholesterolemia 
Low density lipoprotein receptor gene. Low Density Lipoprotein Receptor 
(LDLR) mutation is the main cause for the development of familial 
hypercholesterolemia. LDLR, located on the 
short arm of chromosome 19 shown in Figure 13, 
provides instructions for the production of low-
density lipoprotein receptors (Genetics Home 
Reference, 2014c). Normally, low density 
lipoprotein receptors are located on the outer 
surface of cells and bind with LDL circulating in 
Figure 13: LDLR Gene  
(Genetics Home Reference, 2014c) 
Removed for 
copyright purposes
CHILDHOOD OBESITY 23
the bloodstream to transport them into the cell. Once transported into the cell, LDL is 
then degraded and releases cholesterol, which is then available to be used, stored, or 
excreted. After releasing cholesterol within the cell, LDL receptors return to the surface 
of the cell and the process beings again. Due to their integral part in LDL transport, 
LDLRs regulate the amount of cholesterol in the bloodstream. Familial 
hypercholesterolemia is a result of a mutated LDLR gene; over 1,000 mutations have 
been discovered concerning this gene. Mutations decrease the number of LDL receptors 
produced, causing an inability to remove LDL from the vasculature, resulting in high 
cholesterol levels. If a child inherits one mutated LDLR gene, one affected gene from one 
parent and one normal gene from the other parent, the child has an increased risk of 
cardiovascular disease beginning in their 40s or 50s. If two mutated LDLR genes are 
inherited, one mutated gene from each parent, a severe form of hypercholesterolemia is 
present in childhood. Unfortunately, LDLR gene mutations result in familial 
hypercholesterolemia and predispose children to high cholesterol (Genetics Home 
Reference, 2014c). 
Apolipoprotein B gene. Apolipoprotein B (APOB) is involved in the removal of 
LDL from the vasculature. This gene is located on the short arm of chromosome 2 shown 
Figure 14: APOB Gene (Genetics Home Reference, 2014a) 
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in Figure 14, and provides instructions for making Apolipoprotein B (Genetics Home 
Reference, 2014a). Two forms of Apolipoprotein B are available: Apolipoprotein B-48 
and Apolipoprotein B-100; both forms compose lipoproteins which transport cholesterol 
in the bloodstream. Apolipoprotein B-48, produced in the intestines, is a component of 
chylomicron; after digestion of a meal, chylomicrons are formed to transport fat and 
cholesterol from the intestine to the blood stream. Apolipoprotein B-100, synthesized in 
the liver, is a component of very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), and low-density lipoproteins (LDL) all of which carry fat and 
cholesterol in the vasculature. Apolipoprotein B-100 allows VLDL, IDL, and LDL to 
attach to receptor sites, specifically within the liver. Altered Apolipoprotein B prevents 
LDL from attaching to receptor sites, decreasing the amount of LDL and cholesterol 
removed from the blood stream. Mutations of APOB cause increased levels of serum 
cholesterol and an increased risk of cardiovascular disease (Genetics Home Reference, 
2014a). 
Low density lipoprotein receptor adaptor protein 1 gene. Low Density 
Lipoprotein Receptor Adaptor Protein 1 (LDLRAP1) plays an integral role in the 
transport of cholesterol into the cell. Figure 15 illustrates the position of the LDLRAP1 
 
Figure 15: LDLRAP1 Gene (Genetics Home Reference, 2014d) 
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gene on the short arm of chromosome 1, which codes for a protein that removes 
cholesterol from the bloodstream (Genetics Home Reference, 2014d). The LDLRAP1 
protein is involved in moving LDLR bound to LDL from the surface of the cell to the 
interior of the cell where the cholesterol is released. Gene mutations lead to the synthesis 
of a small dysfunctional LDLRAP1 protein or deficiency of the LDLRAP1 protein. In the 
absence of the LDLRAP1 gene, LDLR is unable to transport LDL from the bloodstream 
into the cell effectively. Although LDL is still able to bind with LDLR, the LDL is not 
properly transported within the cell causing the LDL to remain in the vasculature. The 
mutation of LDLRAP1 contributes to the development of familial hypercholesterolemia 
(Genetics Home Reference, 2014d). 
Proprotein convertase subtilisin/kexin type 9 gene. Proprotein Convertase 
Subtilisin/Kexin Type 9 (PCSK9) contributes to the development of familial 
hypercholesterolemia in children due to a mutated gene. This gene found on the short arm 
of chromosome 1 shown in Figure 16, codes for a protein that helps to regulate the 
amount of cholesterol within the vasculature (Genetics Home Reference, 2014g). PCSK9 
helps to control the amount of LDL receptors present on the surface of liver cells to 
determine the rate of cholesterol removal from the blood. Cholesterol levels are 
Figure 16: PCSK9 Gene (Genetics Home Reference, 2014g) 
Removed for copyright purposes
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controlled by PCSK9 through the degradation of LDL receptors before they reach the 
surface of the cell. In the presence of a mutated PCSK9, one amino acid is altered 
resulting in the enhanced activity of PCSK9. Overactive PCSK9 results in a decreased 
amount of LDL receptors on the cell surface causing increased LDL levels in the blood 
vessels. As a result of deficient LDL receptors, cholesterol increases contributing to 
familial hypercholesterolemia (Genetics Home Reference, 2014g). 
Atherosclerosis 
Definition 
Familial hypercholesterolemia and excess cholesterol contribute to the 
development and progression of atherosclerosis. Atherosclerosis is hardening of the 
arteries from the accumulation of fatty lesions in arteries, particularly the coronary 
arteries (Matfin, 2009). This is a degenerative disease that originates in childhood 
(Raghuveer, 2010). Risk factors for the development of atherosclerosis include both 
modifiable and non-modifiable risk factors such as hypercholesterolemia, family history 
of heart disease, obesity, and male gender (Matfin, 2009). The presence of obesity and 
familial hypercholesterolemia in a child greatly increases the risk of developing heart 
disease at an early age. 
Classification of Atherosclerosis 
Three types of atherosclerosis exist: fatty streaks, fibrous atheromatous plaque, 
and complicated lesions. 
Fatty streaks. Children as young as one year old begin developing fatty streaks, 
independently of other predisposing risk factors (Matfin, 2009). Fatty streaks are 
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composed of macrophages and smooth muscle cells which are part of the vessel wall that 
have become infiltrated with lipids, forming foam cells. As cholesterol levels increase in 
the blood stream, monocytes engulf cholesterol and attach to the endothelium, where they 
then transition through the wall and transform into macrophages. Within the vasculature 
fatty streaks increases until a child reaches age 20, then either decrease or remain 
constant. The Bogalusa Heart Study discovered that 50% of children and 85% of young 
adults had fatty streaks within their arteries, supporting the belief that atherosclerosis 
development begins early in childhood (Eiland & Luttrell, 2010). After the development 
of fatty streaks, atherosclerosis progresses to fibrous atheromatous plaques (Matfin, 
2009). 
 Fibrous atheromatous plaques. Fibrous atheromatous plaques contribute to the 
cardiovascular effects of atherosclerosis. Clinically, these plaques are the most common 
cause of atherosclerosis (Matfin, 2009). Lipids and vascular smooth muscle are the basis 
for fibrous atheromatous plaques, which cause the formation of scar tissue and eventually 
calcification of the plaque. The core of the plaque is composed mainly of cholesterol then 
encapsulated by a fibrous cap and a layer of smooth muscle. As the lesion grows, it 
occludes blood flow within the arteries causing a blockage. As a result of impeding blood 
flow, a myocardial infarction (heart attack) or ischemic infarction (stroke) can occur 
(Matfin, 2009). 
Complicated lesions. Complicated lesions are a result of the combination and 
progression of atherosclerosis. As the fibrous plaque presents with hemorrhage and 
ulceration, platelets accumulate and scar tissue is formed (Matfin, 2009). Activated 
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macrophages release free radicals that oxidize LDL, which is damaging to the
wall and causes hemorrhage.
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As fatty streaks start accumulating in childhood, the presence of excess cholesterol 
aggravates arterial disease and predisposes to myocardial infarction. Atherosclerosis 
results in the occlusion of blood flow to various tissues throughout the body that can 
result in various disease processes. Figure 17 reveals the progression of atherosclerosis 
from birth to age 70 and the disease processes that can result. At birth, atherosclerosis is 
absent, but begins to develop throughout childhood until it is clinically present in middle 
age (Matfin, 2009). 
Pharmacotherapy in Pediatrics 
As a result of the increased prevalence of childhood obesity and familial 
hypercholesterolemia, pharmacotherapy is implemented to decrease cardiovascular 
disease. Childhood obesity with a high fat diet can exacerbate familial 
hypercholesterolemia. Treatment of hypercholesterolemia with pharmacologic agents in 
the pediatric population is controversial due to side effects of medications. Among all 
medications used to control adult cholesterol levels, statins have been found to be 
effective and safe in the treatment of familial hypercholesterolemia in the pediatric 
population (Eiland & Luttrell, 2010). Statins are pharmacologically classified as 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, which reduce 
blood levels of triglycerides and LDL by inhibiting HMG-CoA reductase. 
Pharmacological therapy of familial hypercholesterolemia is relatively new; therefore, no 
specific dosing and treatment criteria have been established. The American Academy of 
Pediatrics recommends treating high cholesterol in children eight years and older if the 
following conditions are met: LDL 
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greater than 190 mg/dL in patients with no risk factors for cardiovascular disease 
if diet modification has been unsuccessful … LDL greater than 160 mg/dL who 
have a family history of premature onset of cardiovascular disease or other risk 
factors including obesity, hypertension, or cigarette smoking, … and LDL greater 
than 130 mg/dL who have diabetes. (The Cleveland Clinic Foundation, 2013, 
para. 4) 
Treatment includes both lifestyle interventions and medication therapy, although diet and 
exercise interventions should be done for six months to one year before initiating 
medication (Eiland & Luttrell, 2010). One exception to this recommendation is that since 
familial hypercholesterolemia is a genetic disease, children may not respond to dietary 
intervention and may require medication earlier. Pravastatin has been approved by the 
FDA for use in children eight years old and up; lovastatin, simvastatin, fluvastatin, 
atorvastatin, and rosuvastatin have been approved by the FDA for children ten years and 
older. Overall, statins have been shown to reduce LDL cholesterol 17 to 50% from a 
child’s baseline level. Side effects of statin use include headache, myalgia, and 
gastrointestinal symptoms, all of which decrease with continued use. Myalgia, known as 
muscle aches and soreness, is the most concerning side effect in children. Children 
suffering from myalgia may have a decreased level of activity, further contributing to 
childhood obesity and an increase in cholesterol levels, which was the initial basis for 
treatment. Nurses must educate children and parents concerning pharmacotherapy to 
enhance their compliance. Overall, it is important to manage cholesterol levels in children 
to decrease their risk of cardiovascular disease (Eiland & Luttrell, 2010). 
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Cardiovascular Disease 
In the presence of familial hypercholesterolemia and childhood obesity, children 
are at an increased risk of developing cardiovascular disease. Across America, obesity 
has become the leading cause of premature heart attack (American Heart Association, 
2011). Extreme body fat seen in obesity is correlated with high cholesterol and 
hypertension, both of which add an increased workload on the heart. Excess cholesterol 
in the bloodstream increases an individual’s risk of developing heart disease and 
atherosclerosis (Genetics Home Reference, 2014b). Damage to the vasculature caused by 
atherosclerosis can result in coronary artery disease or myocardial infarction. Statistics 
reveal that overweight children between the ages of 7 to 13 years old are already at an 
increased risk of developing heart disease beginning at age 25 (American Heart 
Association, 2011). Research shows that 60% of overweight children between the ages 5 
to 10 years old already have one risk factor for heart disease such as high cholesterol, 
high triglycerides, high insulin, or hypertension; 25% of children ages 5 to 10 already 
have two or more heart disease risk factors. As a result of choices made in childhood, 
children are at risk of developing cardiovascular disease that will be present for the 
remainder of their lives. Adolescents who are both obese and have high triglyceride 
levels have arteries similar to 45 year-olds. Childhood obesity affects the vasculature, 
leading to the premature onset and acceleration of atherosclerosis (Raghuveer, 2010). 
Acceleration of atherosclerosis results in cardiovascular effects, such as myocardial 
ischemia and myocardial infarction occurring in children. Unfortunately, due to the 
increase in childhood obesity in past years, coronary artery disease is expected to increase 
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5 to 16% by 2035. The atherosclerosis disease process begins early in childhood and 
progresses into adulthood (American Heart Association, 2012). In the presence of 
childhood obesity and familial hypercholesterolemia, atherosclerosis is exacerbated 
which leads to cardiovascular disease. Childhood obesity and familial 
hypercholesterolemia, both genetic based diseases, contribute to the development of 
cardiovascular disease in children. 
Nurse Role in Preventing Childhood Obesity 
Nurses play a key role in the prevention of modifiable risk factors and education 
of the genetic risk factors of childhood obesity. Education of the entire family unit is 
essential to the prevention of childhood obesity (Rabbitt & Coyne, 2012). Children are 
generally unable to change their eating and health habits alone; therefore, the family unit 
must be involved and participate in changes. 
The nurse can prevent and reduce the occurrence of childhood obesity through 
community and school nursing. In both avenues the nurse can implement education of a 
healthy diet and adequate exercise program for children. A diet high in fruits, vegetables, 
whole grains, low-fat dairy products, and lean meats should be encouraged; additionally, 
a diet low in saturated and trans fats, cholesterol, sodium and added sugars should be 
followed (National Institute of Child Health and Human Development, 2012). Healthcare 
workers can refer families to ChooseMyPlate.gov which is a program developed by the 
USDA to promote healthy eating habits. Adequate exercise for children must also be 
promoted. Children and adolescents need at least 60 minutes of physical activity each day 
(National Institute of Child Health and Human Development, 2012). It is important to 
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tailor the exercise program to the child and include the child in the decision-making 
process to optimize the success of the exercise program. Along with the promotion of 
physical activity, the nurse should insist that sedentary activities be limited to two hours 
per day (Rabbitt & Coyne, 2012). Limiting the amount of time spent playing video 
games, watching television, and playing on the computer will create time for children to 
play outside and be physically active. It is essential that the nurse promotes healthy 
behaviors and does not focus on restrictive diets and over exercising, which could 
predispose a child or adolescent to an eating disorder (Rabbitt & Coyne, 2012). 
Nurses also play a role in educating the public about the role of genetics in the 
development of childhood obesity. Human Genome Research verifies that genes play a 
role in the development of childhood obesity; however, specific environmental factors 
must also be present (Seal, 2011). Not only are nurses involved in education, but also 
have “a crucial role in the prevention and treatment of obesity by identifying the 
modifiable risk factors, evaluating individuals and their families, and collecting detailed 
family health histories” (Seal, 2011, p. 65). Health histories include at least three 
generations and plot out family members and diseases to search for an inheritance 
pattern. Family members should be provided with information about genetic testing 
which is currently only available for monogenic and syndromic forms of obesity. 
Although genetic testing will not prevent childhood obesity, it will allow families to be 
aware that they have a predisposition to obesity. Overall, the nurse plays an integral role 
in the prevention and education of childhood obesity. 
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Childhood obesity has become an epidemic in the United States of America 
within recent years. Research has focused on the genetics of pediatric obesity in order to 
identify gene mutations that disrupt the body’s normal functioning and predispose 
children to disease. Obesity within the pediatric population has led to a surge of high 
cholesterol levels within children, so much so that medications are now administered to 
children to manage this condition. High cholesterol also exacerbates familial 
hypercholesterolemia, a genetically based disease that occurs in children. As a result of 
dysfunction in cholesterol utilization and storage, cholesterol remains within the blood 
stream, increasing the risk of atherosclerosis development. Childhood obesity, familial 
hypercholesterolemia, and atherosclerosis all contribute to the development of 
cardiovascular disease in children. The childhood obesity epidemic must be stopped 
before it steals the lives of America’s children. 
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